Neuromyelitis Optica (Devic’s Syndrome) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Neuromyelitis Optica Pipeline Drugs Market Overview
Neuromyelitis Optica (NMO), also known as Devic’s disease, is an autoimmune condition that means a person’s immune system reacts abnormally and attacks tissues and organs in the body.
The Neuromyelitis Optica pipeline drugs market research report provides an overview of the Neuromyelitis Optica (Devic’s Syndrome) (Central Nervous System) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Neuromyelitis Optica (Devic’s Syndrome) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neuromyelitis Optica (Devic’s Syndrome) (Central Nervous System) and features dormant and discontinued projects.
Neuromyelitis Optica Pipeline Drugs Market by Key Targets
Some of the targets of the Neuromyelitis Optica pipeline drugs market are Complement C5, Cells Expressing B Lymphocyte Antigen CD20, Cells Expressing B Lymphocyte Antigen CD19, IgG Receptor FcRn Large Subunit p51, Tyrosine Protein Kinase BTK, Aquaporin 4, B Lymphocyte Antigen CD20, CD40 Ligand, Cells Expressing B Cell Receptor CD22, and Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 17.
Neuromyelitis Optica Pipeline Drugs Market, by Targets
For more target insights, download a free report sample
Key Mechanisms of Action in the Neuromyelitis Optica Pipeline Drugs Market
Some of the mechanisms of action of the Neuromyelitis Optica pipeline drugs market are Complement C5 Inhibitor, Cytotoxic To Cells Expressing B Lymphocyte Antigen CD20, Cytotoxic To Cells Expressing B Lymphocyte Antigen CD19, IgG Receptor FcRn Large Subunit p51 Antagonist, Tyrosine Protein Kinase BTK Inhibitor, B Lymphocyte Antigen CD20 Inhibitor, CD40 Ligand Inhibitor, Complement C3 Inhibitor, Cytotoxic To Cells Expressing B Cell Receptor CD22, and Cytotoxic To Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 17.
Neuromyelitis Optica Pipeline Drugs Market, by Mechanisms of Action
For more mechanisms of action insights, download a free report sample
Key Routes of Administration in the Neuromyelitis Optica Pipeline Drugs Market
The routes of administration in the Neuromyelitis Optica pipeline drugs market are intravenous, subcutaneous, oral, parenteral, intravenous drip, inhalational, intravitreal, nasal, and topical.
Neuromyelitis Optica Pipeline Drugs Market, by Routes of Administration
For more routes of administration insights, download a free report sample
Key Molecule Types in the Neuromyelitis Optica Pipeline Drugs Market
The molecule types in the Neuromyelitis Optica pipeline drugs market are monoclonal antibody, small molecule, cell therapy, fusion protein, gene-modified cell therapy, protein, recombinant enzyme, recombinant peptide, and synthetic peptide.
Neuromyelitis Optica Pipeline Drugs Market, by Molecule Types
For more molecule type insights, download a free report sample
Key Companies in the Neuromyelitis Optica Pipeline Drugs Market
Some of the key companies in the Neuromyelitis Optica pipeline drugs market are Alexion Pharmaceuticals Inc, HanAll Biopharma Co Ltd, Horizon Therapeutics Plc, Imstem Biotechnology Inc, Tasly Biopharmaceuticals Co Ltd, Accendatech Co Ltd, Aeterna Zentaris Inc, Ahead Therapeutics SL, Apsara Therapeutics, and Beijing Mabworks Biotech Co Ltd.
Neuromyelitis Optica Pipeline Drugs Market, by Companies
To know more about the companies, download a free report sample
Neuromyelitis Optica Pipeline Drugs Market Report Overview
Key Targets | Complement C5, Cells Expressing B Lymphocyte Antigen CD20, Cells Expressing B Lymphocyte Antigen CD19, IgG Receptor FcRn Large Subunit p51, Tyrosine Protein Kinase BTK, Aquaporin 4, B Lymphocyte Antigen CD20, CD40 Ligand, Cells Expressing B Cell Receptor CD22, and Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 17 |
Key Mechanisms of Action | Complement C5 Inhibitor, Cytotoxic To Cells Expressing B Lymphocyte Antigen CD20, Cytotoxic To Cells Expressing B Lymphocyte Antigen CD19, IgG Receptor FcRn Large Subunit p51 Antagonist, Tyrosine Protein Kinase BTK Inhibitor, B Lymphocyte Antigen CD20 Inhibitor, CD40 Ligand Inhibitor, Complement C3 Inhibitor, Cytotoxic To Cells Expressing B Cell Receptor CD22, and Cytotoxic To Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 17 |
Key Routes of Administration | Intravenous, Subcutaneous, Oral, Parenteral, Intravenous Drip, Inhalational, Intravitreal, Nasal, and Topical |
Key Molecule Types | Monoclonal Antibody, Small Molecule, Cell Therapy, Fusion Protein, Gene-Modified Cell Therapy, Protein, Recombinant Enzyme, Recombinant Peptide, and Synthetic Peptide |
Key Companies | Alexion Pharmaceuticals Inc, HanAll Biopharma Co Ltd, Horizon Therapeutics Plc, Imstem Biotechnology Inc, Tasly Biopharmaceuticals Co Ltd, Accendatech Co Ltd, Aeterna Zentaris Inc, Ahead Therapeutics SL, Apsara Therapeutics, and Beijing Mabworks Biotech Co Ltd |
Scope
This report provides:
- A snapshot of the global therapeutic landscape of Neuromyelitis Optica (Devic’s Syndrome) (Central Nervous System).
- Reviews of pipeline therapeutics for Neuromyelitis Optica (Devic’s Syndrome) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- Descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- Reviews of key companies involved in Neuromyelitis Optica (Devic’s Syndrome) (Central Nervous System) therapeutics and enlists all their major and minor projects.
- Evaluation of Neuromyelitis Optica (Devic’s Syndrome) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- All the dormant and discontinued pipeline projects.
- Reviews of the latest news and deals related to pipeline therapeutics for Neuromyelitis Optica (Devic’s Syndrome) (Central Nervous System).
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Neuromyelitis Optica (Devic’s Syndrome) (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Neuromyelitis Optica (Devic’s Syndrome) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Aeterna Zentaris Inc
Ahead Therapeutics SL
Alexion Pharmaceuticals Inc
Apsara Therapeutics
Beijing Mabworks Biotech Co Ltd
Bio-Thera Solutions Ltd
Biogen Inc
Boston Pharmaceuticals Inc
Chord Therapeutics Sarl
Chugai Pharmaceutical Co Ltd
Cour Pharmaceuticals Development Co Inc
Elixiron Immunotherapeutics Inc
Endece LLC
EnhanX Biopharm Inc
Eternity Bioscience Inc
Guangzhou Lupeng Pharmaceutical Co Ltd
H. Lundbeck AS
HanAll Biopharma Co Ltd
Horizon Therapeutics Plc
ImCyse SA
ImmunAbs Inc
Imstem Biotechnology Inc
InnoCare Pharma Ltd
LFB SA
Mitsubishi Tanabe Pharma Corp
Nanjing Iaso Biotherapeutics Co Ltd
NovelMed Therapeutics Inc
Oculis SA
Orion BioScience Inc
PlateletBio
RemeGen Co Ltd
Samsung Bioepis Co Ltd
Shanghai Pharmaceutical Group Co Ltd
SinoMab Bioscience Ltd
Tasly Biopharmaceuticals Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the targets of the Neuromyelitis Optica pipeline drugs market?
Some of the targets of the Neuromyelitis Optica pipeline drugs market are Complement C5, Cells Expressing B Lymphocyte Antigen CD20, Cells Expressing B Lymphocyte Antigen CD19, IgG Receptor FcRn Large Subunit p51, Tyrosine Protein Kinase BTK, Aquaporin 4, B Lymphocyte Antigen CD20, CD40 Ligand, Cells Expressing B Cell Receptor CD22, and Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 17.
-
What are the mechanisms of action of the Neuromyelitis Optica pipeline drugs market?
Some of the mechanisms of action of the Neuromyelitis Optica pipeline drugs market are Complement C5 Inhibitor, Cytotoxic To Cells Expressing B Lymphocyte Antigen CD20, Cytotoxic To Cells Expressing B Lymphocyte Antigen CD19, IgG Receptor FcRn Large Subunit p51 Antagonist, Tyrosine Protein Kinase BTK Inhibitor, B Lymphocyte Antigen CD20 Inhibitor, CD40 Ligand Inhibitor, Complement C3 Inhibitor, Cytotoxic To Cells Expressing B Cell Receptor CD22, and Cytotoxic To Cells Expressing Tumor Necrosis Factor Receptor Superfamily Member 17.
-
What are the routes of administration in the Neuromyelitis Optica pipeline drugs market?
The routes of administration in the Neuromyelitis Optica pipeline drugs market are intravenous, subcutaneous, oral, parenteral, intravenous drip, inhalational, intravitreal, nasal, and topical.
-
What are the molecule types in the Neuromyelitis Optica pipeline drugs market?
The molecule types in the Neuromyelitis Optica pipeline drugs market are monoclonal antibody, small molecule, cell therapy, fusion protein, gene-modified cell therapy, protein, recombinant enzyme, recombinant peptide, and synthetic peptide.
-
Which are the key companies in the Neuromyelitis Optica pipeline drugs market?
Some of the key companies in the Neuromyelitis Optica pipeline drugs market are Alexion Pharmaceuticals Inc, HanAll Biopharma Co Ltd, Horizon Therapeutics Plc, Imstem Biotechnology Inc, Tasly Biopharmaceuticals Co Ltd, Accendatech Co Ltd, Aeterna Zentaris Inc, Ahead Therapeutics SL, Apsara Therapeutics, and Beijing Mabworks Biotech Co Ltd.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.